Linked Life Data

3284210

Source:http://linkedlifedata.com/resource/pubmed/id/3284210

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1988-6-2
pubmed:abstractText
Fluorouracil has been in clinical use as an anticancer drug for 30 years. Although this drug has a broad spectrum of anticancer activity, including significant activity against the common solid tumors of the gastrointestinal system, only a minority of patients treated with fluorouracil experience an objective response to therapy. Furthermore, in randomized clinical trials completed to date, it has not been possible to demonstrate that fluorouracil therapy significantly prolongs the life span of patients with advanced cancer. Recent laboratory studies have indicated that leucovorin can enhance the cytotoxicity of fluorouracil in vitro, evidently by enhancing inhibition of the key enzyme, thymidylate synthetase, by the fluorouracil metabolite, FdUMP (fluorodeoxyuridine monophosphate; a stable inactive FdUMP-reduced folate-thymidylate synthetase complex is formed). Pilot, uncontrolled studies of leucovorin-fluorouracil combinations have suggested that leucovorin may significantly increase both the clinical efficacy and the clinical toxicity of fluorouracil in cancer patients. These findings have led to the initiation of several randomized, controlled studies of leucovorin plus fluorouracil versus fluorouracil alone in the treatment of patients with advanced colorectal cancer. Three of these studies have recently completed patient accrual, and the preliminary results of each of the three studies indicate that leucovorin-fluorouracil combinations will have a better therapeutic index than fluorouracil used alone in this disease. Further follow-up of these studies will be needed to determine whether leucovorin-fluorouracil combination therapy will prolong the life span of patients with colorectal cancer.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/3284210-13418758, http://linkedlifedata.com/resource/pubmed/commentcorrection/3284210-147465, http://linkedlifedata.com/resource/pubmed/commentcorrection/3284210-3099992, http://linkedlifedata.com/resource/pubmed/commentcorrection/3284210-318916, http://linkedlifedata.com/resource/pubmed/commentcorrection/3284210-3487626, http://linkedlifedata.com/resource/pubmed/commentcorrection/3284210-3517242, http://linkedlifedata.com/resource/pubmed/commentcorrection/3284210-3543246, http://linkedlifedata.com/resource/pubmed/commentcorrection/3284210-3874000, http://linkedlifedata.com/resource/pubmed/commentcorrection/3284210-6331882, http://linkedlifedata.com/resource/pubmed/commentcorrection/3284210-6334665, http://linkedlifedata.com/resource/pubmed/commentcorrection/3284210-6704957, http://linkedlifedata.com/resource/pubmed/commentcorrection/3284210-6939434, http://linkedlifedata.com/resource/pubmed/commentcorrection/3284210-6973389, http://linkedlifedata.com/resource/pubmed/commentcorrection/3284210-6982099
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0044-0086
pubmed:author
pubmed:issnType
Print
pubmed:volume
61
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
23-34
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:articleTitle
The effect of leucovorin on the therapeutic index of fluorouracil in cancer patients.
pubmed:affiliation
Lederle Laboratories, Pearl River, NY 10965.
pubmed:publicationType
Journal Article, Clinical Trial, Review